About Primedicine Pharmaceutical
Qingdao Primedicine Pharmaceutical Technology Co., Ltd. is a high-tech enterprise emphasizing on the research and development of first-in-class new drugs, and the development and commercialization of innovative drugs related to the central nervous system in the treatment of drug addiction, Alzheimer's disease, cerebral stroke, depression, schizophrenia, myocardial infarction, etc.
Qingdao Primedicine Pharmaceutical Technology Co., Ltd. is a high-tech enterprise emphasizing on the research and development…
Company obtained the exclusive authorization for the Chinese market from Primary Peptides Inc.…
Chairman—Wang Yutian Tenured Professor, University of British Columbia, Canada …
Third anniversary of Academician Wang Yutian's entry into Qingdao International academician port…
Interfering peptide design platform for targeting protein interaction
Computer Aided Drug Design platform based on protein structure
Pharmacodynamic evaluation platform for neurological disorders
Drug Screening Center
Analysis and Test Center
Pharmacodynamic Evaluation Center
Quality Research Center
Interfering peptide design platform for targeting protein interaction
Computer Aided Drug Design platform based on protein structure
Pharmacodynamic evaluation platform for neurological disorders
Drug Screening Center
Analysis and Test Center
Pharmacodynamic Evaluation Center
Quality Research Center
Interfering peptide design platform for targeting protein interaction
Computer Aided Drug Design platform based on protein structure
Pharmacodynamic evaluation platform for neurological disorders
Drug Screening Center
Analysis and Test Center
Pharmacodynamic Evaluation Center
Quality Research Center
Recently, Qingdao Primedicine Pharmaceutical Technology Co., Ltd. announced that it has successfully completed the preclinical research on two indications of drug addiction and cerebral stroke, and has submitted the research results for pre-investigation of the new drug. It is anticipated that the clinical approval and the subsequent clinical phase I research will be conducted in the second half of 2020.
Recently, Qingdao Primedicine Pharmaceutical Technology Co. Ltd. (hereafter referred as "Primedicine Pharmaceutical") announced that it has obtained the exclusive authorization in China for an innovative polypeptide medicine for treating myocardial infarction from Canada's Primary Peptides Inc (hereafter referred as Primary Peptides).
From January 11th to January 12th, 2020, the first themed 2019 Year-end Meeting team-building activity was held by Qingdao Primedicine Pharmaceutical Technology Co., Ltd. Though the activity lasted only for a day and a half, it left an indelible impression on all employees and increased their camaraderie.
Copyright © 2020 Qingdao Primedicine Pharmaceutical Technology Co., Ltd. All right reserved
